APRE
Aprea Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.01M
P/E Ratio
—
EPS
$-1.93
Beta
1.57
52W High
$2.22
52W Low
$0.55
50-Day MA
$0.75
200-Day MA
$1.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 285,760 |
| Gross Profit (TTM) | $-6.76M |
| EBITDA | $-13.21M |
| Operating Margin | -79206.00% |
| Return on Equity | -74.60% |
| Return on Assets | -41.40% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $1.52 |
| Price-to-Book | 0.66 |
| Price-to-Sales (TTM) | 28.02 |
| EV/Revenue | - |
| EV/EBITDA | 0.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -98.40% |
| Shares Outstanding | $11.45M |
| Float | $10.05M |
| % Insiders | 12.49% |
| % Institutions | 14.81% |
Analyst Ratings
Consensus ($4.40 target)
1
Strong Buy2
BuyData last updated: 4/7/2026